Economic evaluation of everolimus plus exemestane versus bevacizumab plus paclitaxel and bevacizumab plus capecitabine for the management of postmenopausal women with ER+ breast cancer.

Georgia Kourlaba,Vasiliki Rapti,Athanasios Alexopoulos,J. Relakis,Georgios Koumakis,M Chatzikou,Nikolaos Maniadakis,Vassilis Georgoulias

Economic evaluation of everolimus plus exemestane versus bevacizumab plus paclitaxel and bevacizumab plus capecitabine for the management of postmenopausal women with ER+ breast cancer.

2014

Georgia Kourlaba
Vasiliki Rapti
Athanasios Alexopoulos
J. Relakis
Georgios Koumakis
M Chatzikou
Nikolaos Maniadakis
Vassilis Georgoulias

e17638 Background: Estrogen receptor positive (ER+) metastatic breast cancer patients progressing on nonsteroidal aromatase inhibitors are candidates for treatment with everolimus (EVE) plus exemes...

Keywords:

Capecitabine
Breast cancer
Bevacizumab
Exemestane
Physical therapy
Everolimus
Cancer research
Paclitaxel
Medicine
Oncology
Estrogen receptor
Internal medicine
Metastatic breast cancer
Pathology
Aromatase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations